Jane Street
BSTC

Jane Street’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Jane Street’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-16,555
Closed -$446K – 3259
2014
Q2 		$446K Buy
+16,555
New +$431K 0.01% 1508

Other funds holding BSTC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Jane Street's BSTC Position: Q3 2014 in Review

Jane Street sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2014, closing a stake of 16,555 shares — an estimated $446K sold.

Jane Street first reported a position in BSTC in Q2 2014 and held it in 1 quarter. The position peaked at $446K in Q2 2014. 68 funds tracked by Wall St. Rank hold BSTC as of Q3 2014.

  • Jane Street reported no remaining BioSpecifics Technologies Corp. position as of Q3 2014 after selling out during the quarter.
  • Jane Street sold 16,555 BioSpecifics Technologies Corp. shares in Q3 2014, an estimated $446K.
  • Jane Street first reported a position in BioSpecifics Technologies Corp. in Q2 2014 and held it in 1 quarter.
  • Jane Street's BioSpecifics Technologies Corp. position peaked at $446K in Q2 2014.
  • 68 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2014.

Based on Jane Street's 13F filing for Q3 2014, filed 14 Nov 2014.